Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months
In-Pharmatechnologist.com spoke with Missy Lowery, Marketing Manager for the Americas at Capsugel, at this year’s Interphex in New York City about the company’s Fast track Solutions System and its Xcelodose proprietary technology.
“Speed to market is the most important” thing in the pharma market today, she told us.
“Capsugel’s proprietary technology provides an RSD of 1% for quantities as low as 100microgrammes directly into the capsule.”
She told us that Xcelodose was established in order for companies to put APIs directly in a capsule without going through the process of formulation first.
From concept to first clinical trial, Lowery said this technology has sped the whole process up by more than six months.
With “the accuracy of dosing, the continuation of the RSD,” she added, “there is nothing like it on the market right now.”